Health
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence and were well tolerated, with no new safety signals in individuals with moderate-to-severe opioid use disorder (OUD). Participants across both dose groups experienced a rapid reduction in op
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Post-hoc analyses indicated the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting high-frequency fentanyl use.","length":178,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":318,"olType":false},{"type":"text","content":"RICHMOND, Va., Dec. 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence and were well tolerated, with no new safety signals in individuals with moderate-to-severe opioid use disorder (OUD). Participants across both dose groups experienced a rapid reduction in opioid use—from more than 43 instances per week at screening to fewer than three instances per week by week three—a decline maintained through week 38.","length":789,"tagName":"p"},{"type":"image","alt":"Indivior (PRNewsfoto/Indivior)","displaySize":"","headline":null,"caption":"Indivior (PRNewsfoto/Indivior)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":130,"url":"https://media.zenfs.com/en/prnewswire.com/e9a6eb17aaf44dddfab6f7d13d2315b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.uJSnzZQQuSzYp3kZpAAsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e9a6eb17aaf44dddfab6f7d13d2315b7","width":400,"height":130}},"href":"https://mma.prnewswire.com/media/1814851/Indivior_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Post-hoc analyses also identified a subset of individuals who may benefit from the higher 300-mg maintenance dose of extended-release buprenorphine. Participants who used fentanyl daily and/or 14 or more times per week had significantly higher opioid abstinence rates with 300-mg dose compared to 100 mg, suggesting a population that may potential...